Melanoma in organ transplant recipients: clinicopathological features and outcome in 100 cases.
Matin RN., Mesher D., Proby CM., McGregor JM., Bouwes Bavinck JN., del Marmol V., Euvrard S., Ferrandiz C., Geusau A., Hackethal M., Ho WL., Hofbauer GFL., Imko-Walczuk B., Kanitakis J., Lally A., Lear JT., Lebbe C., Murphy GM., Piaserico S., Seckin D., Stockfleth E., Ulrich C., Wojnarowska FT., Lin HY., Balch C., Harwood CA., Skin Care in Organ Transplant Patients, Europe (SCOPE) group None.
Organ transplant recipients have a higher incidence of melanoma compared to the general population but the prognosis of this potentially fatal skin cancer in this group of patients has not yet been established. To address this, we undertook a multicenter retrospective analysis to assess outcome for 100 melanomas (91 posttransplant and 9 pretransplant) in 95 individuals. Data were collected in 14 specialist transplant dermatology clinics across Europe belonging to the Skin Care in Organ Transplant Patients, Europe (SCOPE) Network, and compared with age, sex, tumor thickness and ulceration status-matched controls from the American Joint Committee on Cancer (AJCC) melanoma database. Outcome for posttransplant melanoma was similar to that of the general population for T1 and T2 tumors (< or = 2 mm thickness); but was significantly worse for T3 and T4 tumors (> 2 mm thickness); all nine individuals with a pretransplant melanoma survived without disease recurrence following organ transplantation. These data have implications for both cutaneous surveillance in organ transplant recipients and management of transplant-associated melanoma.